Evidence map›Paper›PMID 42323894›Full record

ArticleBiotechnology and bioengineering2026

Cardiovascular Organoids With Adjustable Endothelial Composition via SOX17-Engineered hPSCs.

Po-Yu Liang, Gyuhyung Jin, Nathan R Petrucci, Xiaojun Lance Lian, Xiaoping Bao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biotechnology and bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Po-Yu LiangDavidson School of Chemical Engineering, Purdue University, West Lafayette, Indiana, USA.
Gyuhyung JinDavidson School of Chemical Engineering, Purdue University, West Lafayette, Indiana, USA.
Nathan R PetrucciWeldon School of Biomedical Engineering, Purdue University, West Lafayette, Indiana, USA.
Xiaojun Lance LianDepartment of Biomedical Engineering, The Pennsylvania State University, University Park, Pennsylvania, USA.
Xiaoping BaoDavidson School of Chemical Engineering, Purdue University, West Lafayette, Indiana, USA.

Funding

Engineer Biomimetic Microfluidic Models to Investigate and Reprogram Tumor Associated Neutrophils for Cancer TherapyR37CA265926 · NCI · PURDUE UNIVERSITY · PI Xiaoping Bao · 2022 to 2026
$1.7M
Stem cell immunoengineering for universal cardiac therapy via CRISPR-Cas9R21EB026035 · NIBIB · PENNSYLVANIA STATE UNIVERSITY, THE · PI LIAN, XIAOJUN · 2018 to 2020
$567k
ModRNA-based Direct Programming of Universal Donor hiPSCs into Immune Evasive Beta CellsR56DK133147 · NIDDK · PENNSYLVANIA STATE UNIVERSITY, THE · PI LIAN, XIAOJUN · 2023 to 2024
$465k
NCI NIH HHS R37 CA265926NCI NIH HHS R37CA265926NIBIB NIH HHS R21 EB026035NIDDK NIH HHS R56 DK133147NIDDK NIH HHS R56DK133147NIH R21EB026035NIH HHS R21EB026035NIH HHS R37CA265926NIH HHS R56DK133147NSF CBET-1943696NSF CBET-2143064NSF CBET-2425704
6 · The paper itself

Abstract

Organoids are considered a novel modeling platform for studying human biology and advancing health research. With the ability to demonstrate complex 3D structure and multicellular interactions, organoids have advanced studies in all major organs as a reliable model. In this study, we generated an advanced cardiovascular organoid by using a genome-edited human pluripotent stem cell line with inducible SOX17 expression, enabling controlled endothelial specification, adjustable cell-type composition, and human heart-like morphology. Our organoids recapitulated the cardiotoxic phenotypes of FDA-approved chemotherapeutic doxorubicin, manifesting as decreased cell viability and diminished contractile activity. Cryoinjury-induced myocardial infarction in our organoids led to reduced beating, viability, and α-actinin expression, along with increased fibroblast formation, which were mitigated by Captopril. Lastly, isoproterenol treatment increased peak Ca

Indexed as

Endothelial CellsMyocytes, CardiacOrganoidsPluripotent Stem CellsSOXF Transcription FactorsCell LineHumansSOX17 protein, humanSOXF Transcription Factorscardiomyocytecardiovascular diseasegenome editinghuman pluripotent stem cellorganoidSOX17

Identifiers

PMID42323894
PMCPMC13551498

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.